Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 30/3/2020
SIETES contiene 92954 citas

 
 
<< anterior 21 a 40 de 157 siguiente >>
Presentar resultados
Seleccionar todas
21. Cita con resumen
Anónimo. Ivacaftor. Une balance bénéfices-risques à mieux cerner. Prescrire 2013;33:328. [Ref.ID 95467]
22.Tiene citas relacionadas
Swigris JJ, Brown KK, Belkin A. Thalidomide for the treatment of cough in idiopathic pulmonary fibrosis. Ann Intern Med 2013;158:498. [Ref.ID 95108]
23.Tiene citas relacionadas
Lechtzin N, Horton MR. Thalidomide for the treatment of cough in idiopathic pulmonary fibrosis. Ann Intern Med 2013;158:498-9. [Ref.ID 95107]
24. Cita con resumen
Anónimo. Colistiméthate poudre à inhaler. Pas mieux que la tobramycine. Prescrire 2013;33:12. [Ref.ID 94671]
25.Tiene citas relacionadas Cita con resumen
Horton MR, Santopietro V, Mathew L, Horton KM, Polito AJ, Liu MC, Danoff SK, Lechtzin N. Thalidomide for the treatment of cough in idiopathic pulmonary fibrosis: a randomized trial. Ann Intern Med 2012;157:398-406. [Ref.ID 93765]
26. Cita con resumen
Chotirmall SH, Smith SG, Gunaratnam C, Cosgrove S, Dimitrov BD, O'Neill SJ, Harvey BJ, Greene CM, McElvaney NG. Effect of estrogen on pseudomonas mucoidy and exacerbations in cystic fibrosis. N Engl J Med 2012;366:1978-86. [Ref.ID 93027]
27. Cita con resumen
Anónimo. Ivacaftor (Kalydeco) for cystic fibrosis. Med Lett Drugs Ther 2012;54:29-30. [Ref.ID 92684]
28.
Miselli M. Colistimetato. Informazioni sui Farmaci 2011;35:25-7. [Ref.ID 91089]
29. Cita con resumen
Anónimo. Pancreatic enzyme products. Med Lett Drugs Ther 2011;53:12. [Ref.ID 90166]
30.
Saiman L, Anstead M, Mayer-Hamblett N, Lands LC, Kloster M, Hocevar-Trnka J, Goss CH, Rose LM, Burns JL, Marshall BC, Ratjen F, for the AZ0004 Azithromycin Study Group. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa. A randomized controlled trial. JAMA 2010;303:1707-15. [Ref.ID 88402]
32.Tiene citas relacionadas
Kerem E, Hirawat S, Armoni S, Yaakov Y, Shoseyov D, Cohen M, Nissim-Rafinia M, Blau H, Rivlin J, Aviram M, Elfring GL, Northcutt VJ, Miller LL, Kerem B, Wilschanski M. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. Lancet 2008;372:719-27. [Ref.ID 83804]
33.Tiene citas relacionadas
Hyde SC, Gill DR. Ignoring the nonsense: a phase II trial in cystic fibrosis. Lancet 2008;372:691-2. [Ref.ID 83798]
34.Tiene citas relacionadas
Allen J, Visner G. Lung transplantation in cystic fibrosis - primum non nocere?. N Engl J Med 2007;357:2186-8. [Ref.ID 81606]
35.Tiene citas relacionadas
Liou TG, Adler FR, Cox DR, Cahill BC. Lung transplantation and survival in children with cystic fibrosis. N Engl J Med 2007;357:2143-52. [Ref.ID 81603]
36.
MacDonald KD, McKenzie KR, Zeitlin PL. Cystic fibrosis transmembrane regulator protein mutations: 'Class' opportunity for novel drug innovation. Pediatr Drugs 2007;9:1-10. [Ref.ID 79544]
37.Tiene citas relacionadas
Poustie VJ, Russell JE, Watling RM, Ashby D, Smyth RL, on behalf of the CALICO Trial Collaborative Group. Oral protein energy supplements for children with cystic fibrosis: CALICO multicentre randomised controlled trial. BMJ 2006;332:632-5. [Ref.ID 76538]
38.Tiene citas relacionadas
Kappler M, Griese M. Nutritional supplements in cystic fibrosis. BMJ 2006;332:618-9. [Ref.ID 76534]
39.
40.Tiene citas relacionadas Cita con resumen
Aaron SD, Vandemheen KL, Ferris W, Fergusson D, Tullis E, Haase D, Berthiaume Y, Brown N, Wilcox P, Yozghatlian V, Bye PTP, Bell S, Chan F, Rose B D, Jeanneret A, Stephenson A, Noseworthy M, Freitag A, Paterson N, Doucette S, Harbour C, Ruel M, MacDonald N. Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial. Lancet 2005;366:463-71. [Ref.ID 74585]
Seleccionar todas
 
<< anterior 21 a 40 de 157 siguiente >>